Karuna Therapeutics Net Income 2011-2026 | KRTX

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Karuna Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-434 M	-276 M	-144 M	-68.6 M	-44 M	-17.5 M	-6.03 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-6.03 M	-434 M	-141 M

Quarterly Net Income Karuna Therapeutics

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-119 M	-103 M	-97.6 M	-	-77 M	-64.9 M	-58.2 M	-	-50.9 M	-34.4 M	-30.5 M	-	-18.8 M	-17 M	-8.66 M	-	-9.04 M	-15.1 M	-12 M	-	-6.24 M	-539 K	-2.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-539 K	-119 M	-40.3 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Acer Therapeutics ACER	-26.2 M	-	2.71 %	$ 14 M	USA
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Adaptimmune Therapeutics plc ADAP	-114 M	-	-15.15 %	$ 60.3 M	Britain
Adverum Biotechnologies ADVM	-131 M	-	-	$ 86.2 M	USA
Aptorum Group Limited APM	-4.27 M	$ 0.83	2.17 %	$ 4.53 M	China
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
I-Mab IMAB	-1.47 B	-	-	$ 866 M	China
Applied Genetic Technologies Corporation AGTC	-18.4 M	-	-	$ 26.5 M	USA
BioNTech SE BNTX	10.3 B	$ 110.14	3.3 %	$ 27.2 B	Germany
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Adagene ADAG	-33.4 M	$ 2.6	-1.12 %	$ 146 M	China
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
AlloVir ALVR	-58.8 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Alterity Therapeutics Limited ATHE	-12.8 M	$ 3.51	-0.52 %	$ 8.45 B	Australia
Applied Molecular Transport AMTI	-126 M	-	-	$ 10.1 M	USA
Can-Fite BioPharma Ltd. CANF	-7.88 M	$ 4.21	1.2 %	$ 9.16 B	Israel
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-253 M	-	-24.86 %	$ 820 K	USA
Akero Therapeutics AKRO	-252 M	-	-	$ 3.67 B	USA
Aeglea BioTherapeutics AGLE	-208 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	-51.9 M	$ 1.49	7.19 %	$ 279 M	USA
Aptose Biosciences APTO	-25.4 M	-	-45.71 %	$ 1.2 M	Canada
Albireo Pharma ALBO	-34 M	-	-0.23 %	$ 916 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-384 M	$ 221.8	-0.16 %	$ 5 B	Danmark
Allena Pharmaceuticals ALNA	-48.7 M	-	3.16 %	$ 1.9 M	USA
Aptinyx APTX	-64.8 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	-76.3 M	-	-13.39 %	$ 1.45 M	USA
Arena Pharmaceuticals ARNA	-616 M	-	-6.81 %	$ 3.04 B	USA
Aridis Pharmaceuticals ARDS	-30.4 M	-	17.91 %	$ 11.1 M	USA
Burford Capital Limited BUR	172 M	$ 8.96	0.45 %	$ 1.41 B	Britain
Aeterna Zentaris AEZS	-8.37 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-14.8 M	-	-10.17 %	$ 12.2 K	USA
Athira Pharma ATHA	-96.9 M	-	-	$ 269 M	USA
Athersys ATHX	-87 M	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-86.7 M	-	0.23 %	$ 488 M	USA
Avenue Therapeutics ATXI	-11.7 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-221 M	$ 1.46	2.46 %	$ 373 M	Britain
Amneal Pharmaceuticals AMRX	-73.9 M	$ 14.49	-0.24 %	$ 4.48 B	USA
AIkido Pharma AIKI	-14.7 M	-	1.93 %	$ 17.4 M	USA
AVROBIO AVRO	12.2 M	-	1083.1 %	$ 745 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-13.6 M	$ 2.35	-1.81 %	$ 14.8 M	USA
AstraZeneca PLC AZN	115 M	-	-	$ 96.9 B	Britain
Brickell Biotech BBI	-5.69 M	-	-5.38 %	$ 6.06 M	USA